Pacific Biosciences Of California (PACB) Profit After Tax Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Profit After Tax Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 16.04% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 99.26% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | 4.70% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 89.28% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -27.13% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 108.33% |
| 10 | Pacific Biosciences Of California | 415.91 Mn | 139.95 Mn | 12.84 Mn | -20,082.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,082.93% |
| Dec 31, 2025 | -3,993.06% |
| Sep 30, 2025 | -1,923.31% |
| Jun 30, 2025 | 99.93% |
| Mar 31, 2025 | 99.95% |
| Dec 31, 2024 | 101.30% |
| Sep 30, 2024 | 103.14% |
| Jun 30, 2024 | -148.19% |
| Mar 31, 2024 | 10.58% |
| Dec 31, 2023 | 5.24% |
| Sep 30, 2023 | 15.11% |
| Jun 30, 2023 | 2.19% |
| Mar 31, 2023 | -4.16% |
| Dec 31, 2022 | -21.72% |
| Jun 30, 2022 | -74.13% |
| Mar 31, 2022 | 3.36% |
| Dec 31, 2021 | -192.42% |
| Jun 30, 2021 | -79.26% |
| Mar 31, 2021 | -6,893.71% |
| Dec 31, 2020 | 82,534.07% |